Somatrem
Somatrem is a recombinant human growth hormone used for the treatment of short stature due to decreased or absent secretion of endogenous growth hormone. Somatrem was first marketed under the brand name Protropin by Genentech in 1985[1]. It differs from endogenous growth hormone by the addition of an extra methionine at the N-terminus[2]. Somatrem has largely been replaced by somatropin, marketed by several companies including by Genentech as the brand Nutropin.
| Clinical data | |
|---|---|
| Trade names | Protropin |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C995H1537N263O301S8 |
| Molar mass | 22256.26 g·mol−1 |
  | |
Somatrem is an analogue of growth hormone (GH).
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.